Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $112000.0.

  • Ernexa Therapeutics' Other Non-Current Liabilities rose 17317.07% to $112000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $112000.0, marking a year-over-year increase of 17317.07%. This contributed to the annual value of $111000.0 for FY2024, which is 431.03% down from last year.
  • As of Q3 2025, Ernexa Therapeutics' Other Non-Current Liabilities stood at $112000.0, which was up 17317.07% from $113000.0 recorded in Q2 2025.
  • Ernexa Therapeutics' 5-year Other Non-Current Liabilities high stood at $19.4 million for Q3 2021, and its period low was $41000.0 during Q3 2024.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $185500.0 (2023), whereas its average is $4.3 million.
  • In the last 5 years, Ernexa Therapeutics' Other Non-Current Liabilities skyrocketed by 12850000.0% in 2021 and then tumbled by 9717.61% in 2023.
  • Over the past 5 years, Ernexa Therapeutics' Other Non-Current Liabilities (Quarter) stood at $19.4 million in 2021, then crashed by 98.29% to $331000.0 in 2022, then crashed by 64.95% to $116000.0 in 2023, then dropped by 4.31% to $111000.0 in 2024, then rose by 0.9% to $112000.0 in 2025.
  • Its Other Non-Current Liabilities stands at $112000.0 for Q3 2025, versus $113000.0 for Q2 2025 and $111000.0 for Q1 2025.